O. Yu

First name
O.
Middle name
H.
Last name
Yu
Fournier, J. P., Yin, H., Yu, O. H., & Azoulay, L. (2014). Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. Cmaj. http://doi.org/10.1503/cmaj.140688
View
Yu, O. H., Filion, K. B., Azoulay, L., Patenaude, V., Majdan, A., & Suissa, S. (2015). Incretin-based drugs and the risk of congestive heart failure. Diabetes Care. http://doi.org/10.2337/dc14-1459
View
Yu, O. H., Yin, H., & Azoulay, L. (2015). The combination of DPP-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2015.02.002
View
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016). Pioglitazone use and risk of bladder cancer: population based cohort study. Bmj. http://doi.org/10.1136/bmj.i1541
View
Hicks, B. M., Yin, H., Yu, O. H., Pollak, M. N., Platt, R. W., & Azoulay, L. (2016). Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. Bmj. http://doi.org/10.1136/bmj.i5340
View
Faillie, J. L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016). Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus. JAMA Intern Med. http://doi.org/10.1001/jamainternmed.2016.1531
View
Abrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., et al. (2018). Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. Bmj. http://doi.org/10.1136/bmj.k4880
View
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018). Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy. Diabetes Care. http://doi.org/10.2337/dc17-2280
View
Filion, K. B., Douros, A., Azoulay, L., Yin, H., Yu, O. H., & Suissa, S. (2019). Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.14056
View